A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)

Clinical trial NCT05704725 · COMPLETED

Trial details

NCT number: NCT05704725
Sponsor: Amgen
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Chorioretinal Vascular Disease

Start date: 2023-01-23
Primary completion: 2023-02-17
Enrollment: 49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.